within Pharmacolibrary.Drugs.D_Dermatologicals.D06B_ChemotherapeuticsForTopicalUse.D06BA51_SilverSulfadiazineCombinations;

model SilverSulfadiazineCombinations
  extends Pharmacolibrary.Drugs.ATC.D.D06BA51;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D06BA51</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Silver sulfadiazine, in combination drugs, is a topical antimicrobial used primarily as a cream to prevent and treat infections in burns and wounds. It has broad-spectrum antibacterial activity due to the combined effects of silver and the sulfonamide component. It is approved and widely used for burn wound management.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic models or quantitative PK parameters for silver sulfadiazine combinations are reported in the literature. Due to its primarily topical use and minimal systemic absorption, especially in intact skin, pharmacokinetic data is scarce. This record is based on general estimates for topical use in adults with moderate burns.</p><h4>References</h4><ol><li><p>Hollinger, MA (1996). Toxicological aspects of topical silver pharmaceuticals. <i>Critical reviews in toxicology</i> 26(3) 255–260. DOI:<a href=&quot;https://doi.org/10.3109/10408449609012524&quot;>10.3109/10408449609012524</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8726163/&quot;>https://pubmed.ncbi.nlm.nih.gov/8726163</a></p></li><li><p>Sanchez, MF, et al., &amp; Olivera, ME (2018). Ciprofloxacin-lidocaine-based hydrogel: development, characterization, and in vivo evaluation in a second-degree burn model. <i>Drug delivery and translational research</i> 8(5) 1000–1013. DOI:<a href=&quot;https://doi.org/10.1007/s13346-018-0523-7&quot;>10.1007/s13346-018-0523-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29654411/&quot;>https://pubmed.ncbi.nlm.nih.gov/29654411</a></p></li><li><p>Mi, FL, et al., &amp; Hao, JY (2002). Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. <i>Journal of biomedical materials research</i> 59(3) 438–449. DOI:<a href=&quot;https://doi.org/10.1002/jbm.1260&quot;>10.1002/jbm.1260</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11774301/&quot;>https://pubmed.ncbi.nlm.nih.gov/11774301</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end SilverSulfadiazineCombinations;
